You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Acasti Pharma raises further C$1.5M via offering of units
Identifying PPE Suppliers During the Pandemic
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Canada's Acasti Pharma Inc. agreed to issue about C$1.5 million of units to the underwriter of its recently closed securities offering, which helped raise C$10 million.
The underwriter, Mackie Research Capital Corp., exercised its overallotment option to buy an additional 1,429,500 units at C$1.05 each from the company.
Acasti Pharma will use the net proceeds from the offering and overallotment to advance its drug pipeline.